Back to top

gene-editing: Archive

Zacks Equity Research

SRPT Q1 Earnings Miss, Sales Beat, Stock Slides 21% on '25 View Cut

SRPT reports mixed first-quarter 2025 results. The stock plunges after the company significantly lowers its 2025 sales guidance.

RHHBYPositive Net Change SRPTPositive Net Change ARWRPositive Net Change

Zacks Equity Research

SRPT Provides Pipeline Updates on Rare Muscular Disorder Therapies

Following positive FDA feedback, Sarepta advances a fourth LGMD program to clinical development.

RHHBYPositive Net Change SRPTPositive Net Change ANIPPositive Net Change CTMXNegative Net Change

Zacks Equity Research

VERV Stock Soars on Superior Efficacy in Phase I Cholesterol Study

Verve Therapeutics stock rises on demonstrating superior LDL-C lowering ability in a phase Ib study of VERVE-102 in patients with HeFH and/or CAD.

LLYNegative Net Change BAYRYPositive Net Change ADMAPositive Net Change VERVPositive Net Change

Sundeep Ganoria

Biotech Stocks Fall After Top FDA Official Quits Over Clash With RFK Jr.

The decline in biotech stocks comes after FDA official Peter Marks' resignation, citing irreconcilable differences with the new HHS Secretary.

MRNAPositive Net Change NVAXNegative Net Change SRPTPositive Net Change CRSPPositive Net Change PCVXPositive Net Change

Ekta Bagri

Promising Genomics & Synthetic Biology Stocks to Consider in 2025

Investors interested in the Genomics and Synthetic Biology theme should consider these stocks: Twist Bioscience Corporation, Wave Life Sciences, and CRISPR Therapeutics AG.

ILMNPositive Net Change BEAMPositive Net Change WVEPositive Net Change NTLAPositive Net Change CRSPPositive Net Change TWSTPositive Net Change